Insilico Medicine launched a benchmark-as-a-service for AI drug discovery, positioning it as a way to test whether frontier models can make meaningful scientific decisions rather than simply retrieve training data. The company described the offering as a Drug Discovery and Development Benchmark as a Service, aimed at strengthening evaluation methodologies for generative systems. The announcement targets a known limitation in many AI benchmarks: performance can reflect memorization or benchmark-leakage rather than scientific reasoning. By providing a managed testing framework, Insilico aims to produce more decision-relevant assessments for model outputs. For biotech stakeholders, the development is relevant because translational decision-making—target selection, lead optimization, and study design—depends on evaluation quality to reduce downstream cost of experimentation. Insilico’s move suggests growing competition in applied AI verification tools, not only in model development.